tbuckley/cabot-search huggingface dataset:
RADIOBIOLOGY
Authors: J. W. Boag
Journal: BMJ (1962)

<h3>BACKGROUND:</h3> Secretion removal is a key issue in patients with respiratory diseases, and is known to be most effective at vibration frequencies of ∼13 Hz and with the greatest amplitudes possible. The Acapella devices and the water bottle are used for secretion removal in daily clinical practice but without detailed knowledge on optimal settings. The aim of this study was to evaluate the 3 different Acapella devices and the water bottle at various settings and flows to determine the optimal devices and settings for effective secretion removal. <h3>METHODS:</h3> Three different Acapella devices were tested at flows of 6, 12, 20, 30, 40, and 50 L/min, and at all 5 settings. The water bottle was filled with 5, 10, or 15 cm of water, and tested at flows of 3, 6, 10, 12, and 20 L/min. For all devices and combinations of settings, we measured the frequency and amplitude of the vibrations, as well as the required pressure to generate vibrations. <h3>RESULTS:</h3> Setting 4 was the best for all 3 Acapella devices, and the filling height of the water bottle should be 5 cm. At these settings, all devices elicited vibration frequencies between 12 and 15 Hz, which is theoretically optimal for secretion mobilization. The resistance pressures of the devices to elicit these vibrations were between 5 and 11 cm H<sub>2</sub>O. However, the Acapella devices elicit higher vibration amplitudes (5–8 cm H<sub>2</sub>O) than the water bottle (1.8 cm H<sub>2</sub>O) <h3>CONCLUSIONS:</h3> Setting 4 was optimal for all 3 Acapella devices. The Acapella devices may be more efficient for secretion mobilization than the water bottle, because they elicit greater amplitude of vibrations.
Involvement of the Tracheobronchial Tree in South American Blastomycosis
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
COMPARATIVE THERAPEUTIC VALUE OF DIGITALIS AND ITS DERIVATIVES.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nocebos Contribute to Host of Ills
Authors: Rebecca Voelker
Journal: JAMA (1996)

HERBERT BENSON, MD, still recalls the time a patient nearly made him sick. The incident happened during his internship, as Benson was about to examine an Asian man. When the patient came into the examining room, Benson says he "absolutely panicked." In a cold sweat, his heart racing, the physician performed the exam. But afterward, he told the patient of his unusual reaction. The patient's response? "Ha, ha, ha, Yank. Now you die!" he exclaimed, recreating his Tokyo Joe film role from World War II—era movies. Just the sight of the character actor evoked in Benson a response similar to how he had felt while watching those films. "Wired in me was this fear. When I saw him, although I couldn't identify the fear, it expressed itself," explains Benson, now president of the Mind &amp; Body Medical Institute at Harvard Medical School, Boston, Mass. Benson's anecdote illustrates a little-recognized aspect
A SYSTEM OF PERSONAL BIOLOGIC EXAMINATIONS—THE CONDITION OF ADEQUATE MEDICAL AND SCIENTIFIC CONDUCT OF LIFE.
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Survival and Function of Bioengineered Cardiac Grafts
Authors: Ren-Ke Li, Zhi-Qiang Jia, Richard D. Weisel, Donald A. G. Mickle, Angel Choi, Terrence M. Yau
Journal: Circulation (1999)

Introduction —Patients with congenital heart disease frequently require graft material for repair of cardiac defects. However, currently available grafts lack growth potential and are noncontractile and thrombogenic. We have developed a viable cardiac graft that contracts spontaneously in tissue culture by seeding cells derived from fetal rat ventricular muscle into a biodegradable material. We report our investigations of the in vitro and in vivo survival and function of this bioengineered cardiac graft. Methods and Results —A cardiomyocyte-enriched cell inoculum derived from fetal rat ventricular muscle was seeded into a piece of Gelfoam (Upjohn, Ontario, Canada), a biodegradable gelatin mesh, to form the graft. For in vitro studies, growth patterns of the cells within the graft were evaluated by constructing growth curves and by histologic examination; in in vivo studies, the graft was cultured for 7 days and then implanted either into the subcutaneous tissue of adult rat legs or onto myocardial scar tissue in a cryoinjured rat heart. Five weeks later, the graft was studied histologically. The inoculated cells attached to the gelatin mesh and grew in 3 dimensions in tissue culture, forming a beating cardiac graft. In both the subcutaneous tissue and the myocardial scar, blood vessels grew into the graft from the surrounding tissue. The graft implanted into the subcutaneous tissue contracted regularly and spontaneously. When implanted onto myocardial scar tissue, the cells within the graft survived and formed junctions with the recipient heart cells. Conclusions —Fetal rat ventricular cells can grow 3-dimensionally in a gelatin mesh. The cells in the graft formed cardiac tissue and survived and contracted spontaneously both in tissue culture and after subcutaneous implantation. Future versions of this bioengineered cardiac graft may eventually be used to repair cardiac defects.
Insufficient Anaesthesia
Authors: E. H. Winterbottom
Journal: BMJ (1950)

Dr. Rickman has, in fact, written of the development of psycho-analysis, and nobody is better qualified to do so.But it is a pity that your "Fifty Years of Medicine" number did not include a review of the development of psychiatry.This would include an impressive body of material which would interest (and perhaps convince) the general reader more than an account of the development of one school of psychopathological theory.-Iam, etc.
Calcified coronary artery aneurysms
Authors: R. Ellis
Journal: JAMA (1968)

Calcified coronary aneurysm associated with marked abdominal aortic calcification and stenosis of the left renal artery occurred in a young Filipino woman. Conventional roentgenograms of the chest adequately demonstrated the coronary artery aneurysm. Takayasu's arteriopathy is suggested as a possible etiologic factor.
银屑病患者中的非酒精性脂肪肝
Authors: R.B. Prussick, L. Miele
Journal: British Journal of Dermatology (2018)

银屑病是一种片状、发红、鳞状的慢性皮疹,大约2%的人口受其困扰。银屑病患者虽然通常身体健康,但相比他人更容易患上关节炎、代谢综合征(MetS:2型糖尿病、高血压和肥胖)以及被称为非酒精性脂肪肝(NAFLD)的肝脏疾病。NAFLD以肝脏中过多脂肪沉积开始,但是可能进展到炎症(非酒精性脂肪性肝炎,NASH)、肝硬化,甚至是肝癌。本论文来自美国和意大利的研究人员,评述了银屑病和NAFLD之间的关联:银屑病患者的发病率是非银屑病患者的两倍以上,并且更为严重。银屑病患者患上NAFLD的风险随着年龄和银屑病严重程度的增加而增加,即使剔除氨甲喋呤(一种治疗银屑病的有效药物,已知会导致肝损伤)的影响。两种病情下,肥胖(脂肪因子)产生的致炎化学物水平都会增加,而抗炎脂肪因子水平会降低。脂肪因子会在能量均衡、胰岛素敏感性、血压、血管维护以及炎症方面发挥作用。肝脏通过产生肝脏因子来响应脂肪因子,而这可促进MetS和NAFLD。涉及这些和其他身体化学物质的多步骤流程存在复杂的反馈回路,会造成肝细胞死亡和再生之间的不均衡,从而导致NAFLD。银屑病患者的炎症反应会促成这一流程。本评述强调了监控银屑病患者整体健康的重要性,并提出了某些抗炎药物能同时缓解两种疾病的可能性。
SIR WILLIAM COWERS (1845-1915)
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35/98
Authors: M. E. Ghielmini, S. Hsu Schmitz, G. Martinelli, F. Peccatori, U. Hess, M. Fey, E. Zucca, R. Stahel, N. Ketterer, T. Cerny
Journal: Journal of Clinical Oncology (2009)

8512 Background: In FL, rituximab as a single agent obtains a response rate of 50–70% with an EFS of 1–3 years depending on the population studied. Some patients respond to this treatment for a prolonged time, so we investigated, in a clinical trial, the proportion of long-term responders and the characteristics predicting long-term response. Methods: Between 1998 and 2002, chemotherapy naïve (n = 64) or pre-treated (n = 138) FL patients received 4 weekly doses of rituximab: those responding or with stable disease were randomized to either no further treatment (observation, n = 78) or 4 additional doses of rituximab given at 2 months intervals (consolidation, n = 73). Results: At a median follow up of 8.9 years, and with all living patients having been followed for at least 5 years, the median event-free survival (EFS: time until progression, relapse, second tumor or death) is 13 months for the observation and 24 months for the consolidation arm (p=0.0012). In the observation arm 10% had no event at 5-years, the figure dropping to 4% (3/78) at 8 years, while in the consolidation arm the EFS was 26% at 5 years and remained 18% (13/73) at 8 years. The only significant prognostic factor for EFS in a multivariate Cox regression was having received consolidation rituximab (hazard ratio = 0.58, CI = 0.44–0.87, p = 0.008), whereas being chemotherapy naïve, presenting with stage &lt; IV and showing a VV phenotype at position 158 of the Fc receptor RIIIA were not any more significantly prognostic in this long term analysis, in contrast to previous data with shorter follow-up. No long-term toxicity from treatment was observed. There were 21 cases of second malignancy: 11 on observation, 10 receiving the consolidation arm. Conclusions: It appears that the EFS advantage of prolonged versus short course rituximab continues for many years after the end of treatment. This seems to hold true independently from previous treatment, stage or 158-phenotype of the Fc receptor. Patients treated with 8 doses of rituximab over 1 year have approximately 25% and 20% chance to remain in remission at 5 and 8 years respectively. [Table: see text]
Occult Thyrotoxicosis
Authors: RICHARD P. LEVY
Journal: Annals of Internal Medicine (1970)

Letters and Comments1 February 1970Occult ThyrotoxicosisRICHARD P. LEVY, M.D.RICHARD P. LEVY, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-72-2-286 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Rose, Sanders, Webb, and Hines (Ann Intern Med 71:309, 1969) correctly call attention to factitial ingestion of thyroid hormone as a cause of hyperthyroidism. Although all three patients whom they describe denied taking any thyroid hormone, there seems to be little question that Patients 2 and 3 were doing so. The diagnosis in Patient 1 is open to some doubt, and the data presented can be interpreted differently than was done by the authors.First, both the 3-hr and 24-hr thyroid131I uptakes can be considered normal, especially in this era of iodine-rich bread (1, 2). Second,...References1. PITTMANDAILEYBESCHI JGR: Changing normal values for thyroidal radioiodine uptake. New Eng J Med 280:1431, 1969 CrossrefMedlineGoogle Scholar2. JEFFERIESLEVYPALMER WRW: The value of a single injection of thyrotropin in the diagnosis of obscure hypothyroidism. New Eng J Med 249:876, 1953 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Departments of Medicine and Radiology Case Western Reserve University School of Medicine Cleveland, Ohio 44106 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 February 1970Volume 72, Issue 2Page: 286-286KeywordsBreadHyperthyroidismIngestionThyroidThyroid hormones ePublished: 1 December 2008 Issue Published: 1 February 1970 PDF downloadLoading ...
Abstract 21017: A Systematic Review and Meta-Analysis on Success and Complications of Epicardial Access
Authors: Mohit K Turagam, Scott Koerber, Venkat Vuddanda, Sudarshan Balla, Donita Atkins, Luigi Di Biase, Andrea Natale, Dhanunjaya Lakkireddy
Journal: Circulation (2017)

Background: Epicardial access (EA) is increasingly used in various electrophysiological procedures with wide variation in EA success and complications. Methods: A comprehensive search was performed in PubMed, EBSCO and Google Scholar databases for studies reporting success and complications with EA. Meta-analysis was done using MedCalc software with random effects-model. Procedural success was defined as successful pericardial access. Pericardial tamponade was defined as pericardial effusion requiring drainage. Success and complications were adjusted and calculated per 100 procedures. Results: A total of 6 studies [retrospective - 5, prospective - 1] including 1,122 patients [large bore (LB) - 878, micropuncture (MP) - 219 and EpiAcces- 25 patients] undergoing EA for ventricular tachycardia ablation and Lariat procedure. Table 1,2 demonstrates rates of procedural success and complications of EA. Acute procedural success was 94.9% [95% CI (93.1 - 96.1)]. Pericardial tamponade, pericardial effusion, emergency heart surgery and RV puncture were seen in 1.7%, 2.8%, 0.7% and 6.5% respectively. Conclusion: EA is feasible with a 95% procedural success and acceptable rate of major complications. Use of MP needle and advancement in other EA technology will further improve procedure safety.
QUALITY OF LIFE
Authors: M. R. Lucas, K. M. Robinson, E.-S. Koh, E. J. Hovey, K. M. Wright, T. Simpson, M. A. Price, J. Shafiq, N. Kaadan, M. B. Barton, T. Armstrong, J. S. Wefel, M. Wang, M. Won, A. Bottomley, T. R. Mendoza, C. Coens, M. Werner-Wasik, D. G. Brachman, A. K. Choucair, M. Mehta, M. R. Gilbert, J. Spezeski, S. M. de Melo, L. P. Taylor, H. Otero, M. A. Zuurveld, S. M. Peerdeman, G. J. Bouma, R. E. Feller, M. Klein, N. K. Aaronson, M. J. B. Taphoorn, J. J. Heimans, T. J. Postma, C. M. Gundy, G. N. Beute, B. J. Slotman, M. Klein, D. Satoer, A. Vincent, C. Dirven, M. Smits, E. Visch-Brink, E. Vera-Bolanos, T. S. Armstrong, T. Mendoza, A. Fisher, C.-W. Kuo, P. Sherwood, K. B. Peters, A. D. Coan, M. J. West, D. A. Reardon, A. Desjardins, J. J. Vredenburgh, H. S. Friedman, L. W. Jones, A. A. Acquaye, L. Lin, A. S. Aspenson, J. Cahill, E. Vera-Bolanos, M. R. Gilbert, T. S. Armstrong, T. Lamki, M. Ammirati, L. Lin, A. A. Acquaye, E. Vera-Bolanos, J. Cahill, M. R. Gilbert, T. S. Armstrong, L. Lin, A. A. Acquaye, E. Vera-Bolanos, J. Cahill, M. R. Gilbert, T. S. Armstrong, J.-S. Lai, A. Acquaye, T. S. Armstrong, A. A. Acquaye, L. Lin, A. C. Aspenson, J. Cahill, E. Vera-Bolanos, M. R. Gilbert, T. S. Armstrong, B. V. Stell, D. I. Jacobs, S. A. Grimm, A. Rademaker, L. Rice, M. Schwartz, J. Chandler, K. Muro, I. B. Helenowki, M. H. Marymont, L. I. Wagner, M. Mehta, J. Raizer, M. E. Gerard, J. Drappatz, A. Muzikansky, S. Weiss, S. Kesari, E. Wong, C. E. Fadul, A. D. Norden, E. C. Quant, R. Beroukhim, B. Alexander, S. Ruland, A. S. Ciampa, D. C. LaFrankie, C. Sceppa, K. H. Smith, S. N. Hammond, P. Y. Wen, E. Farace, J. Sheehan, R. Bonneau, M. Glantz, K. L. McDonald, S. Ryu, J. Rock, R. Jain, C. Casas, L. Schultz, M. Pace, T. Aho, M. Horio, P. Doshi, J. Cahill, N. Padhye, E. Vera-Bolanos, I. Gning, T. Mendoza, M. Gilbert, T. Armstrong, J. M. Hoover, J. Mandrekar, F. B. Meyer, I. F. Parney
Journal: Neuro-Oncology (2011)
Cancer invasion and metastases
Authors: L. A. Liotta
Journal: JAMA (1990)

<h3>SELECTED CASE</h3> EIGHT years ago, a 62-year-old woman sought evaluation for an asymptomatic 2-cm mammographic abnormality in the upper part of the outer quadrant of her left breast. The results of an incisional biopsy were indicative of malignancy. After staging evaluation revealed no distant metastatic disease, she under-went a modified radical mastectomy with axillary node dissection. At the time of pathological review, a 2 × 2-cm estrogen receptor—positive infiltrating ductal adenocarcinoma was found; axillary lymph nodes were free of tumor (stage II, T2, NO, MO). Follow-up was uneventful until presentation 1 year ago, when the patientdeveloped progressive dyspnea on exertion, orthopnea, a dry cough, and a heaviness in the left side of her chest. At the time of examination, she was tachypneic and tachycardiac, and physical findings included dullness to percussion and absent left-sided breath sounds; she was admitted for treatment. A chest roentgenogram showed an opacified left hemithorax and
Breakthrough and interferon dose in the therapy of chronic hepatitis C Internal Medicine, Niguarda Hospital, Milan; *Chair Internal Medicine, S. Gerardo Hospital, Monza; UInternal Medicine, Bolognini Hospital, Seriate; ?Internal Medicine, Mestre Hospital, Venezia; **Gastroenterology Unit, Molinette Hospital, Torino; IChronic Hepatitis Study Group; Italy
Journal: Hepatology (1995)
Genetic counseling and prevention of birth defects
Journal: JAMA (1982)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PAUL GERSON UNNA (1850-1929) DERMATOLOGIST OF EIMSBÜttle
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Percutaneous interventions fo coronary bypass grafts have doubled major adverse events Marco Roffi, Debabarata Mukherjee, Deepak L. Bhatt, Derek P. Chew, Khaled M. Ziada, Danielle M. Prosper, Stephen G. Ellis, Eric J. Topol. Cleveland Clinic Foundation, Cleveland, OH
Journal: Journal of the American College of Cardiology (2001)